Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhejiang Univ. ROCK2 compound 10d: sourced facts only. name: "Exploiting this structural feature through virtual screening led to the discovery of compound 10d, a potent ROCK2 inhibitor with markedly improved selectivity compared to the reference compound KD025." [PMID:41574563]; target: "Exploiting this structural feature through virtual screening led to the discovery of compound 10d, a potent ROCK2 inhibitor with markedly improved selectivity compared to the reference compound KD025." [PMID:41574563]; developer: "Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China." [PMID:41574563]; stage: "In a mouse model of MC903-induced AD, 10d effectively suppressed inflammation and achieved therapeutic efficacy superior to the model group, while maintaining a favorable safety profile." [PMID:41574563]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhejiang Univ. ROCK2 compound 10d.